Quark, Nitto Denko Collaborate on RNAi Drugs for Fibrotic Disease | GenomeWeb

Quark Pharmaceuticals announced this week that it has formed a collaboration with Japan's Nitto Denko to develop siRNA-based drugs for fibrotic diseases.

The deal, Quark said, will combine its expertise and intellectual property related to siRNA design with Nitto Denko's drug-delivery technologies.

The collaboration will have an initial budget in the "double-digit" millions of dollars, and is expected to yield an investigational new drug application by early 2012, Quark added.

Additional terms were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.